Interleukin-3 and granulocyte-macrophage colony-stimulating factor expression, a biomarker of memory CD8+ T cell immunity and vaccine efficacy

Journal of Vaccines and Vaccination

Volumn 3, Issue 8, 2012, Pages

  Trivedi, Shubhanshi ^a   Jackson, Ronald ^a   Ranasinghe, Charani ^a  

^a Australian National University   (Australia)

Author keywords

HIV vaccines; IL 13R 2; IL 3 GM CSF; Memory CD8+ T cells; Poxvirus prime boost

Indexed keywords

EID: 84879809972     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000166     Document Type: Article

References (49)

1. Hapel AJ, Fung MC, Johnson RM, Young IG, Johnson G, et al. (1985) Biologic properties of molecularly cloned and expressed murine interleukin-3. Blood 65: 1453-1459.
2. Yang YC, Ciarletta AB, Temple PA, Chung MP, Kovacic S, et al. (1986) Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47: 3-10.
3. Morris CF, Young IG, Hapel AJ (1990) Molecular and cellular biology of interleukin-3. Immunol Ser 49: 177-214.
4. Donahue RE, Seehra J, Metzger M, Lefebvre D, Rock B, et al. (1988) Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241: 1820-1823.
5. Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, et al. (1986) Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 68: 46-57.
6. Sonoda Y, Yang YC, Wong GG, Clark SC, Ogawa M (1988) Analysis in serumfree culture of the targets of recombinant human hemopoietic growth factors: interleukin 3 and granulocyte/macrophage-colony-stimulating factor are specific for early developmental stages. Proc Natl Acad Sci USA 85: 4360-4364.
7. Ganser A, Lindemann A, Ottmann OG, Seipelt G, Hess U, et al. (1992) Sequential in vivo treatment with 2 recombinant human hematopoietic growthfactors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis-results of a phase-I study. Blood 79: 2583-2591.
8. Oshaughnessy JA, Venzon DJ, Gossard M, Noone MH, Denicoff A, et al. (1995) A phase-I study of sequential versus concurrent interleukin-3 and granulocytemacrophage colony-stimulating factor in advanced breast-cancer patients treated with flac (5-Fluorouracil, Leucovorin, Doxorubicin, Cyclophosphamide) chemotherapy. Blood 86: 2913-2921.
9. Eder M, Geissler G, Ganser A (1997) IL-3 in the clinic. Stem Cells 15: 327-333.
10. Siracusa MC, Saenz SA, Hill DA, Kim BS, Headley MB, et al. (2011) TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 477: 229-233.
11. Ranasinghe C, Eyers F, Stambas J, Boyle DB, Ramshaw IA, et al. (2011) A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunizations. Vaccine 29: 3008-3020.
12. Srivastava RK, Tomar GB, Barhanpurkar AP, Gupta N, Pote ST, et al. (2011) IL-3 attenuates collagen-induced arthritis by modulating the development of Foxp3+ regulatory T cells. J Immunol 186: 2262-2272.
13. Kim S, Prout M, Ramshaw H, Lopez AF, LeGros G, et al. (2010) Cutting edge: basophils are transiently recruited into the draining lymph nodes during helminth infection via IL-3, but infection-induced Th2 immunity can develop without basophil lymph node recruitment or IL-3. J Immunol 184: 1143-1147.
14. O'Neill E, Martinez I, Villinger F, Rivera M, Gascot S, et al. (2002) Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol 31: 217-227.
15. Andrew M, Morris K, Coupar B, Sproat K, Oke P, et al. (2006) Porcine interleukin-3 enhances DNA vaccination against classical swine fever. Vaccine 24: 3241-3247.
16. Hellerstein M, Xu Y, Marino T, Lu S, Yi H, et al. (2012) Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine. Hum Vaccin Immunother 8.
17. Kelleher AD, Puls RL, Bebbington M, Boyle D, Ffrench R, et al. (2006) A randomised, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 20: 294-297.
18. Hemachandra A, Puls RL, Sirivichayakul S, Kerr S, Thantiworasit P, et al. (2010) An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin 6: 835-840.
19. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, et al. (2011) A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 29: 7514-7522.
20. Ottenhoff TH, Kaufmann SH (2012) Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 8: e1002607.
21. Aagaard CS, Hoang TT, Vingsbo-Lundberg C, Dietrich J, Andersen P (2009) Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 183: 2659-2668.
22. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, et al. (2009) Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113: 3978-3989.
23. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, et al. (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63-77.
24. Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C (2011) Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol Cell Biol 89: 367-374.
25. Ranasinghe C, Trivedi S, Stambas J, Jackson RJ (2012) Unique IL-13R α2 based HIV-1 vaccine strategy to enhance mucosal immunity, CD8+ T cell avidity and protective immunity. Mucosal Immunol.
26. Boyle DB, Anderson MA, Amos R, Voysey R, Coupar BE (2004) Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques 37: 104-106,108-111.
27. Boyle DB, Coupar BE, Both GW (1985) Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene 35: 169-177.
28. Coupar BEH, Purcell DFJ, Thomson SA, Ramshaw IA, Kent SJ, et al. (2006) Fowlpox virus vaccines for HIV and SIV clinical and pre-clinical trials. Vaccine 24: 1378-1388.
29. Ranasinghe C, Medveczky JC, Woltring D, Gao K, Thomson S, et al. (2006) Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for highlevel mucosal and systemic immunity against HIV-1. Vaccine 24: 5881-5895.
30. Ranasinghe C, Turner SJ, McArthur C, Sutherland DB, Kim JH, et al. (2007) Mucosal HIV-1 pox virus prime-boost immunization Induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 178: 2370-2379.
31. Ranasinghe C, Ramshaw IA (2009) Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity. Eur J Immunol 39: 1819-1830.
32. Burgers WA, Chege GK, Muller TL, van Harmelen JH, Khoury G, et al. (2009) Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 90: 468-480.
33. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
34. Listvanova S, Temmerman S, Stordeur P, Verscheure V, Place S, et al. (2003) Optimal kinetics for quantification of antigen-induced cytokines in human peripheral blood mononuclear cells by real-time PCR and by ELISA. J Immunol Methods 281: 27-35.
35. Day SL (2008) Evaluation of interferon responses and activity for effective vaccine therapy. Canberra: The Australiana National University.
36. Gerondakis S, Strasser A, Metcalf D, Grigoriadis G, Scheerlinck JY, et al. (1996) Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 93: 3405-3409.
37. Liou HC, Jin Z, Tumang J, Andjelic S, Smith KA, et al. (1999) c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 11: 361-371.
38. Banerjee D, Liou HC, Sen R (2005) c-Rel-dependent priming of naive T cells by inflammatory cytokines. Immunity 23: 445-458.
39. Symeonidou I, Kourelis A, Frydas I, Karagouni E, Anogeianaki A, et al. (2010) Modulation of NF-kappaBeta signalling pathways by parasites. J Biol Regul Homeost Agents 24: 471-479.
40. Lelchuk R, Carrier M, Kahl L, Liew FY (1989) Distinct IL-3 activation profile induced by intravenous versus subcutaneous routes of immunization. Cell Immunol 122: 338-349.
41. Kiyono H, Fukuyama S (2004) NALT-versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 4: 699-710.
42. Mirabella F, Baxter EW, Boissinot M, James SR, Cockerill PN (2010) The human IL-3/granulocyte-macrophage colony-stimulating factor locus is epigenetically silent in immature thymocytes and is progressively activated during T cell development. J Immunol 184: 3043-3054.
43. Belyakov IM, Ahlers JD (2009) What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 183: 6883-6892.
44. Ito K, Shinohara N, Kato S (2003) DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response. Mol Immunol 39: 847-854.
45. Rosada RS, de la Torre LG, Frantz FG, Trombone AP, Zarate-Blades CR, et al. (2008) Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol 9: 38.
46. Pemberton RM, Smythies LE, Mountford AP, Wilson RA (1991) Patterns of cytokine production and proliferation by T lymphocytes differ in mice vaccinated or infected with Schistosoma mansoni. Immunol 73: 327-333.
47. Min L, Mohammad Isa SA, Shuai W, Piang CB, Nih FW, et al. (2010) Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J Immunol 184: 4625-4629.
48. Wong KL, Tang LF, Lew FC, Wong HS, Chua YL, et al. (2009) CD44 high memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production. J Immunol 183: 41-50.
49. Schluns KS, Lefrancois L (2003) Cytokine control of memory T-cell development and survival. Nat Rev Immunol 3: 269-279.